0001104659-14-071316.txt : 20141112 0001104659-14-071316.hdr.sgml : 20141111 20141010164355 ACCESSION NUMBER: 0001104659-14-071316 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20141010 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Forward Pharma A/S CENTRAL INDEX KEY: 0001604924 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: ?STERGADE 24A, 1 CITY: COPENHAGEN STATE: G7 ZIP: 1100 BUSINESS PHONE: 0114533444242 MAIL ADDRESS: STREET 1: ?STERGADE 24A, 1 CITY: COPENHAGEN STATE: G7 ZIP: 1100 CORRESP 1 filename1.htm

 

October 10, 2014

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn:  Jeffrey P. Riedler

 

Re:                             Forward Pharma A/S

Registration Statement on Form F-1

File No. 333-198013

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Forward Pharma A/S (the “Registrant”) hereby requests, subject to telephone confirmation, that the effectiveness of the above-captioned Registration Statement, relating to a public offering of American Depositary Shares representing ordinary shares of the Registrant, nominal value DKK 0.10 per share, be accelerated so that it will become effective as of 4:30 p.m. EDT on October 14, 2014, or as soon thereafter as practicable.

 

The Registrant acknowledges that:

 

1. should the Securities and Exchange Commission (the “Commission”) or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;

 

2. the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and

 

3. the Registrant may not assert Staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

[Signature page follows]

 


 

Very truly yours,

 

 

 

Forward Pharma A/S

 

 

 

/s/ Peder Møller Andersen

 

 

 

Peder Møller Andersen

 

Chief Executive Officer